{"denoms":[{"counts":[{"groupId":"BG000","value":"1"}],"units":"Participants"}],"groups":[{"description":"Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\\^2 intravenously on Days 1, 4, 8, 11.","id":"BG000","title":"Vorinostat + Bortezomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"48","upperLimit":"48","value":"48"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}